α-Internexin: A Novel Biomarker for Pancreatic Neuroendocrine Tumor Aggressiveness

Liu, Bei; Tang, Laura H.; Liu, Zhaojun; Mei, Mei; Yu, Run; Dhall, Deepti; Qiao, Xinwei; Zhang, Taiping; Zhao, Yuanhui; Liu, Tonghua; Xiao, Yu; Chen, Jie; Xiang, Hongding; Wu, Haiyan; Chen, Lu; Lv, Bin; Zhou, Yaru; Zhang, Ye; Deng, Dajun; Chen, Yuan‐Jia

doi:10.1210/jc.2013-2874

Cited by 25 publications

(35 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, INA is overexpressed in pancreas neuroendocrine tumors and positively correlated with the proliferation rate, tumor size, an infiltrative growth behavior and tumor grading. Here, decreased levels of mRNA and protein were associated with a significantly lower tumor proliferation [16,56]. Our findings in pituitary tumors do not consistently support a possible correlation of INA expression and important clinicopathological factors.…”

Section: Discussioncontrasting

confidence: 73%

Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 73%

Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The criteria of semi-quantitative grading of IHC was similar to our previous report [36,39], i.e. (−) means no positive staining in tumor cells; (±) < 20% tumor cells shown positive staining, (+) ≥20% but < 50% tumor cells shown positive staining; (++) ≥50% but < 75% tumor cells shown positive staining; (+++) ≥ 75% tumor cells shown positive staining.…”

Section: Methodsmentioning

confidence: 67%

“…The diagnostic criteria for PNETs were reported previously [33-39]. Briefly, the tumors were mainly localized by computed tomography with contrast, magnetic resonance imaging, endoscopic ultrasound and somatostatin receptor scintigraphy.…”

Section: Methodsmentioning

confidence: 99%

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundPancreatic neuroendocrine tumors (PNETs) are a group of rare tumors. Chromogranin A (CgA) was considered as the most practical and useful serum tumor marker in PNET patients. But peripheral blood levels of CgA are not routinely tested in Chinese patients with PNETs. This study was to assess the diagnostic value of CgA in Chinese patients with PNETs especially in patients with insulinomas.MethodsEighty-nine patients with PNETs including 57 insulinomas and 32 non-insulinoma PNETs as well as 86 healthy participants were enrolled in this study between September 2003 and June 2013. Serum levels of CgA were measured by ELISA method. Expression of CgA protein was detected in 26 PNET tissues including 14 insulinomas by immunohistochemical staining.ResultsSerum levels of CgA in 89 PNET patients were significantly higher than that in healthy controls (P = 7.2 × 10−9). Serum levels of CgA in 57 patients with insulinomas (median 64.8 ng/ml, range 25–164) were slightly higher than the levels in healthy controls (median 53.4 ng/ml, range 39–94) but much lower than the levels in 32 patients with non-insulinoma PNETs (median 193 ng/ml, range 27–9021), P = 0.001. The serum CgA levels were reduced in 16 of 17 patients with insulinomas after tumor resection. ROC curve showed that CgA values at 60 ng/ml distinguished patients with insulinomas from healthy controls but its sensitivity and specificity were 66.7% and 73.3%, respectively. In contrast, CgA values at 74 ng/ml distinguished patients with non-insulinoma PNETs from healthy controls, and the sensitivity and specificity were 65.6% and 91.9%, respectively. Except for two insulinomas with negative staining of CgA, 12 insulinoma tissues showed positive staining of CgA.ConclusionCgA is a reliable serum diagnostic biomarker for PNETs but not for insulinomas.

show abstract

“…Close observation may be required to small pNETs (9,10). Therefore, biomarkers that reflect the aggressive features of pNETs are urgently required in order to aid therapeutic decisions and follow-up observations (11).…”

Section: Introductionmentioning

confidence: 99%

“…It has been widely used in the management of gastrointestinal malignancies, particularly for pancreatic cancer (11,13). In a pool data analysis of CA19-9 for the diagnosis of pancreatic cancer, the median sensitivity was 79% (70-90%) and the median specificity was 82% (68-91%) (14).…”

Section: Introductionmentioning

confidence: 99%

Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors

Luo

Jin

et al. 2017

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Abstract. Carbohydrate antigen 19-9 (CA19-9) is not generally considered to be a biomarker in pancreatic neuroendocrine tumors (pNETs), as the majority of pNETs present with a normal range of CA19-9. The present study aimed to evaluate the role of serum CA19-9 levels as a prognostic factor in a relatively large number of patients with pNETs. Consecutive patients were retrospectively collected from a single institution between June 2006 and February 2015. The receiver operating characteristic (ROC) curve and the area under the ROC curve were used to select the cut-off values for the baseline CA19-9 levels. The primary end point was set as overall survival. Potential factors associated with the abnormal elevation of CA19-9 expression levels in pNETs were also investigated. The cut-off value for CA19-9 was 16 U/ml as determined by the ROC curve, and for the area under the ROC curve it was 0.68. In total, 32.7% of patients (51/156) had CA19-9 expression levels higher than the cut-off value. Univariate analysis demonstrated that CA19-9 >16 U/ml was an adverse prognostic factor for patients' overall survival. The CA19-9 >16 U/ml group had a statistically higher proportion of tumor node metastasis (TNM) stage III or IV, as compared with the CA19-9 ≤16 U/ml group. To the best of our knowledge, the present study is the first to demonstrate that CA19-9 is a prognostic biomarker of pNETs, one that may reflect its aggressiveness and severity.

show abstract

α-Internexin: A Novel Biomarker for Pancreatic Neuroendocrine Tumor Aggressiveness

Abstract: α-Internexin can be a useful prognostic biomarker for PNETs.

Cited by 25 publications

References 42 publications

Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors

Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas

Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors

Contact Info

Product

Resources

About